Articles
Page 1 of 3
-
Citation: Genetic Vaccines and Therapy 2012 10:10
-
DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?
Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immun...
Citation: Genetic Vaccines and Therapy 2012 10:9 -
Targeting wild-type Erythrocyte receptors for Plasmodium falciparum and vivax Merozoites by Zinc Finger Nucleases In- silico: Towards a Genetic Vaccine against Malaria
Malaria causes immense human morbidity and mortality globally. The plasmodium species vivax and falciparum cause over 75 % clinical malaria cases. Until now, gene-based strategies against malaria have only been a...
Citation: Genetic Vaccines and Therapy 2012 10:8 -
Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model
Liver fluke can infect cattle and sheep, and is also emerging as a human pathogen in developing countries. Cathepsin B (Cat B2) is a major cysteine protease secreted by the juvenile flukes. To enhance the immu...
Citation: Genetic Vaccines and Therapy 2012 10:7 -
A brief review on dengue molecular virology, diagnosis, treatment and prevalence in Pakistan
Dengue virus infection is a serious health problem infecting 2.5 billion people worldwide. Dengue is now endemic in more than 100 countries, including Pakistan. Each year hundreds of people get infected with d...
Citation: Genetic Vaccines and Therapy 2012 10:6 -
A combination of intradermal jet-injection and electroporation overcomes in vivodose restriction of DNA vaccines
The use of optimized delivery devices has been shown to enhance the potency of DNA vaccines. However, further optimization of DNA vaccine delivery is needed for this vaccine modality to ultimately be efficacio...
Citation: Genetic Vaccines and Therapy 2012 10:5 -
Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan
Gp41 is an envelope glycoprotein of human immune deficiency virus (HIV). HIV viral glycoprotein gp41, present in complex with gp120, assists the viral entry into host cell. Over eighty thousands individuals ar...
Citation: Genetic Vaccines and Therapy 2012 10:4 -
An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery
The appropriate tropism of adeno-associated virus (AAV) vectors that are systemically injected is crucial for successful gene therapy when local injection is not practical. Acidic oligopeptides have been shown...
Citation: Genetic Vaccines and Therapy 2012 10:3 -
Treatment of adult MPSI mouse brains with IDUA-expressing mesenchymal stem cells decreases GAG deposition and improves exploratory behavior
Mucopolysaccharidosis type I (MPSI) is caused by a deficiency in alpha-L iduronidase (IDUA), which leads to lysosomal accumulation of the glycosaminoglycans (GAGs) dermatan and heparan sulfate. While the curre...
Citation: Genetic Vaccines and Therapy 2012 10:2 -
Molecular relationship between field and vaccine strain of measles virus and its persistence in Pakistan
Countrywide 5.9 million, 0-11 Month old children are immunized annually by EPI (Expended Program on Immunization) against 8 vaccine preventable diseases including measles and so on. Unfortunately the basic imm...
Citation: Genetic Vaccines and Therapy 2012 10:1 -
HCV entry receptors as potential targets for siRNA-based inhibition of HCV
Hepatitis C virus (HCV) is a major health concern with almost 3% of the world's population (350 million individuals) and 10% of the Pakistani population chronically infected with this viral pathogen. The curre...
Citation: Genetic Vaccines and Therapy 2011 9:15 -
Occult HCV or delayed viral clearance from lymphocytes of Chronic HCV genotype 3 patients after interferon therapy
A recently discovered occult HCV entity reported by various investigators seems to be highly controversial. Especially, the clinical significance of these findings remains uncertain. For optimal outcome of ant...
Citation: Genetic Vaccines and Therapy 2011 9:14 -
Biodistribution and blood clearance of plasmid DNA administered in arginine peptide complexes
Peptide/DNA complexes have great potential as non-viral methods for gene delivery. Despite promising results for peptide-mediated gene delivery technology, an effective systemic peptide-based gene delivery sys...
Citation: Genetic Vaccines and Therapy 2011 9:13 -
Establishment of stable Huh-7 cell lines expressing various hepatitis C virus genotype 3a protein: an in-vitro testing system for novel anti-HCV drugs
Hepatitis C virus (HCV) infection is the leading cause of chronic hepatitis which progresses to hepatocellular carcinoma (HCC) afflicting > 170 million people worldwide. HCV 3a is the most common genotype (abo...
Citation: Genetic Vaccines and Therapy 2011 9:12 -
Antiviral drugs against hepatitis C virus
Hepatitis C virus (HCV) infection is a major worldwide problem causes acute and chronic HCV infection. Current treatment of HCV includes pegylated interferon-α (PEG IFN- α) plus ribavirin (RBV) which has signi...
Citation: Genetic Vaccines and Therapy 2011 9:11 -
Comparative analysis of macrophage associated vectors for use in genetic vaccine
Antigen presentation by non professional antigen presenting cells (APC) can lead to anergy. In genetic vaccines, targeting the macrophages and APC for efficient antigen presentation might lead to balanced immu...
Citation: Genetic Vaccines and Therapy 2011 9:10 -
A comparison of multiple shRNA expression methods for combinatorial RNAi
RNAi gene therapies for HIV-1 will likely need to employ multiple shRNAs to counter resistant strains. We evaluated 3 shRNA co-expression methods to determine their suitability for present use; multiple expres...
Citation: Genetic Vaccines and Therapy 2011 9:9 -
Altering α-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism
The envelope glycoprotein of lymphocytic choriomeningitis virus (LCMV) can efficiently pseudotype lentiviral vectors. Some strains of LCMV exploit high affinity interactions with α-dystroglycan (α-DG) to bind ...
Citation: Genetic Vaccines and Therapy 2011 9:8 -
In-vitro model systems to study Hepatitis C Virus
Hepatitis C virus (HCV) is a major cause of chronic liver diseases including steatosis, cirrhosis and hepatocellular carcinoma. Currently, there is no vaccine available for prevention of HCV infection due to h...
Citation: Genetic Vaccines and Therapy 2011 9:7 -
Double suicide genes driven by kinase domain insert containing receptor promoter selectively kill human lung cancer cells
To investigate the selective killing efficacy of the double suicide genes driven by KDR promoter.
Citation: Genetic Vaccines and Therapy 2011 9:6 -
B cells Can Modulate the CD8 Memory T Cell after DNA Vaccination Against Experimental Tuberculosis
Although B cells are important as antigen presenting cells (APC) during the immune response, their role in DNA vaccination models is unknown.
Citation: Genetic Vaccines and Therapy 2011 9:5 -
In vitro evaluation of a double-stranded self-complementary adeno-associated virus type2 vector in bone marrow stromal cells for bone healing
Both adenoviral and lentiviral vectors have been successfully used to induce bone repair by over-expression of human bone morphogenetic protein 2 (BMP-2) in primary rat bone marrow stromal cells in pre-clinica...
Citation: Genetic Vaccines and Therapy 2011 9:4 -
Plasmid-encoded NP73-102 modulates atrial natriuretic peptide receptor signaling and plays a critical role in inducing tolerogenic dendritic cells
Atrial natriuretic peptide (ANP) is an important endogenous hormone that controls inflammation and immunity by acting on dendritic cells (DCs); however, the mechanism remains unclear.
Citation: Genetic Vaccines and Therapy 2011 9:3 -
Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan
Hepatitis C virus (HCV) is one of the leading causes of viral hepatitis worldwide and its genotype 3a is predominant in vast areas of Pakistan.
Citation: Genetic Vaccines and Therapy 2011 9:2 -
Influence of insulators on transgene expression from integrating and non-integrating lentiviral vectors
The efficacy and biosafety of lentiviral gene transfer is influenced by the design of the vector. To this end, properties of lentiviral vectors can be modified by using cis-acting elements such as the modificatio...
Citation: Genetic Vaccines and Therapy 2011 9:1 -
AAV2-mediated in vivo immune gene therapy of solid tumours
Many strategies have been adopted to unleash the potential of gene therapy for cancer, involving a wide range of therapeutic genes delivered by various methods. Immune therapy has become one of the major strat...
Citation: Genetic Vaccines and Therapy 2010 8:8 -
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation
Immunization of mice with tumor homogenate after combined treatment with cyclophosphamide (CP) and double-stranded DNA (dsDNA) preparation is effective at inhibition of growth of tumor challenged after the tre...
Citation: Genetic Vaccines and Therapy 2010 8:7 -
Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice
Impaired wound healing in diabetes is related to decreased production of growth factors. Hence, gene therapy is considered as promising treatment modality. So far, efforts concentrated on single gene therapy w...
Citation: Genetic Vaccines and Therapy 2010 8:6 -
Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensischallenge
We have previously demonstrated protective efficacy against B. melitensis using formulations of naked DNA vaccines encoding genes ialB and omp25. The present study was undertaken to further understand the immune ...
Citation: Genetic Vaccines and Therapy 2010 8:5 -
Development of avian influenza virus H5 DNA vaccine and MDP-1 gene of Mycobacterium bovisas genetic adjuvant
Studies have shown that DNA vaccines can induce protective immunity, which demonstrated the high potential of DNA vaccines as an alternative to inactivated vaccines. Vaccines are frequently formulated with adj...
Citation: Genetic Vaccines and Therapy 2010 8:4 -
Recombinant λ-phage nanobioparticles for tumor therapy in mice models
Lambda phages have considerable potential as gene delivery vehicles due to their genetic tractability, low cost, safety and physical characteristics in comparison to other nanocarriers and gene porters. Little...
Citation: Genetic Vaccines and Therapy 2010 8:3 -
Protection against the allergic airway inflammation depends on the modulation of spleen dendritic cell function and induction of regulatory T cells in mice
Allergen-induced imbalance of specific T regulatory (Treg) cells and T helper 2 cells plays a decisive role in the development of immune response against allergens.
Citation: Genetic Vaccines and Therapy 2010 8:2 -
Optimised electroporation mediated DNA vaccination for treatment of prostate cancer
Immunological therapies enhance the ability of the immune system to recognise and destroy cancer cells via selective killing mechanisms. DNA vaccines have potential to activate the immune system against specif...
Citation: Genetic Vaccines and Therapy 2010 8:1 -
Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression
Murine retroviral vectors have been used in several hundred gene therapy clinical trials, but have fallen out of favor for a number of reasons. One issue is that gene expression from viral or internal promoter...
Citation: Genetic Vaccines and Therapy 2009 7:13 -
Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice
When cyclophosphamide and preparations of fragmented exogenous genomic double stranded DNA were administered in sequence, the regressive effect on the tumor was synergic: this combined treatment had a more pro...
Citation: Genetic Vaccines and Therapy 2009 7:12 -
Dietary restriction abrogates antibody production induced by a DNA vaccine encoding the mycobacterial 65 kDa heat shock protein
Protein-calorie malnutrition (PCM) is the most common type of malnutrition. PCM leads to immunodeficiency and consequent increased susceptibility to infectious agents. In addition, responses to prophylactic va...
Citation: Genetic Vaccines and Therapy 2009 7:11 -
Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models
Vascular endothelial growth factor (VEGF) and its receptor, VEGFR-2 (Flk-1/KDR), play a key role in tumor angiogenesis. Blocking the VEGF-VEGFR-2 pathway may inhibit tumor growth. Here, we used human VEGFR-2 a...
Citation: Genetic Vaccines and Therapy 2009 7:10 -
AAV-mediated gene therapy for metabolic diseases: dosage and reapplication studies in the molybdenum cofactor deficiency model
In a mouse model for molybdenum cofactor deficiency as an example for an inherited metabolic disease we have determined the dosage of recombinant AAV necessary to rescue the lethal deficiency phenotype. We dem...
Citation: Genetic Vaccines and Therapy 2009 7:9 -
Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5
The use of shRNAs to downregulate the expression of specific genes is now relatively routine in experimentation but still hypothetical for clinical application. A potential therapeutic approach for HIV-1 disea...
Citation: Genetic Vaccines and Therapy 2009 7:8 -
Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen
Hepatitis C core protein is an attractive target for HCV vaccine aimed to exterminate HCV infected cells. However, although highly immunogenic in natural infection, core appears to have low immunogenicity in e...
Citation: Genetic Vaccines and Therapy 2009 7:7 -
Assessment of methods and analysis of outcomes for comprehensive optimization of nucleofection
Nucleofection is an emerging technology for delivery of nucleic acids into both the cytoplasm and nucleus of eukaryotic cells with high efficiency. This makes it an ideal technology for gene delivery and siRNA...
Citation: Genetic Vaccines and Therapy 2009 7:6 -
Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours
The most common cause of death of cancer sufferers is through the occurrence of metastases. The metastatic behaviour of tumour cells is regulated by extracellular growth factors such as hepatocyte growth facto...
Citation: Genetic Vaccines and Therapy 2009 7:5 -
A new plasmid vector for DNA delivery using lactococci
The use of food-grade lactococci as bacterial carriers to DNA delivery into epithelial cells is a new strategy to develop live oral DNA vaccine. Our goal was to develop a new plasmid, named pValac, for antigen...
Citation: Genetic Vaccines and Therapy 2009 7:4 -
Erratum to: Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice
Citation: Genetic Vaccines and Therapy 2009 7:3 -
The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model
Tyrosine kinase inhibitor gefitinib is effective against lung cancer cells carrying mutant epidermal growth factor receptor (EGFR); however, it is not effective against lung cancer carrying normal EGFR. The br...
Citation: Genetic Vaccines and Therapy 2009 7:2 -
Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer
The delivery of therapeutic genes to the central nervous system (CNS) using viral vectors represents an appealing strategy for the treatment of nerve injury and disorders of the CNS. Important factors determin...
Citation: Genetic Vaccines and Therapy 2009 7:1 -
Comparison of electrically mediated and liposome-complexed plasmid DNA delivery to the skin
Electroporation is an established technique for enhancing plasmid delivery to many tissues in vivo, including the skin. We have previously demonstrated efficient delivery of plasmid DNA to the skin utilizing a cu...
Citation: Genetic Vaccines and Therapy 2008 6:16 -
Genetic immunization with Hantavirus vaccine combining expression of G2 glycoprotein and fused interleukin-2
In this research, we developed a novel chimeric HTNV-IL-2-G2 DNA vaccine plasmid by genetically linking IL-2 gene to the G2 segment DNA and tested whether it could be a candidate vaccine. Chimeric gene was fir...
Citation: Genetic Vaccines and Therapy 2008 6:15 -
Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle
The purpose of this study was to assess the behavior of pseudotyped recombinant adeno-associated virus type 1 (rAAV2/1) vector genomes in dystrophic skeletal muscle. A comparison was made between a therapeutic...
Citation: Genetic Vaccines and Therapy 2008 6:14 -
Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice
The AAV9 capsid displays a high natural affinity for the heart following a single intravenous (IV) administration in both newborn and adult mice. It also results in substantial albeit relatively lower expressi...
Citation: Genetic Vaccines and Therapy 2008 6:13